Accelerate Diagnostics (AXDX)
(Delayed Data from NSDQ)
$0.86 USD
+0.09 (11.56%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $0.83 -0.03 (-3.38%) 4:40 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Price, Consensus and EPS Surprise
AXDX 0.86 +0.09(11.56%)
Will AXDX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AXDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AXDX
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics
AXDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System
Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?
Other News for AXDX
Analysts Have Conflicting Sentiments on These Healthcare Companies: Staar Surgical (STAA), DarioHealth (DRIO) and Accelerate Diagnostics (AXDX)
Accelerate Diagnostics price target lowered by $1 at Craig-Hallum, here's why
Stockholders Beware: Accelerate Diagnostics’ Surge in Authorized Shares Signals Potential Dilution Risk
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
AXDX Stock Earnings: Accelerate Diagnostics Misses EPS, Misses Revenue for Q4 2023